Is the Bull Run in Biotech over?

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

In a bull market that’s six-plus years old, bull runs in hot sectors become increasingly scarce commodities.

One sector that’s been the lead bull pulling this bull market cart forward is biotech.

But even this raging bull could be in need of a breather.

The biotech sector has been the top performer in the market over much of the past 12 months.

In fact, it has been the secret of many of the best hedge fund managers who have counted on the biotech boom to keep them delivering big gains.

In the interest of full disclosure, the Market Vectors Biotech ETF (BBH) is a current recommendation in my Alpha Investor Letter service.

I’m very happy to admit that.

After all, the biotech sector has enjoyed a stellar run over the past 52 weeks, surging nearly 40%.

Yet over the past month, this same exchange-traded fund (ETF) has actually tipped slightly into the red.

As the overall equity market begins to stall, could we begin to see the stocks leading the charge higher launch a substantial correction?

If so, does this mean that the bull run in biotech is over?

A Noisy Bubble Debate

A recent article in London’s Financial Times described current conditions in the biotech sector.

It highlighted the “noisy debate” of whether biotech stocks are now in a bubble, or whether we are just seeing a much-overdue correction within a larger bull market.

BBH_081115

The Financial Times piece quoted advisors on both sides of the biotech bull run question.

Charles Heenan, investment director at Edinburgh-based Kennox Asset Management, argued that biotech is a bubble about to burst. As Heenan points out, “The sector can move quickly without much change to fundamentals. When it goes right, it goes very right. But when it goes wrong, investors could lose it all.”

Exclusive  GM Announces $1.3B Expansion of 5 U.S. Plants

On the pro-biotech side is Neil Woodford, fund manager of the namesake Woodford Investment Management. Woodford, the best-known fund manager in the United Kingdom today, is famous both for finding small gems to invest in and for having the best long-term track record among his peers.

Most importantly for us, Woodford is a big bull on pharmaceuticals and biotech.

Thanks to several big biotech winners, Woodford Investment Management has delivered a 16.9% gain over the past 12 months through June 30. That compares with a drop of 7.7% for the iShares MSCI EAFE (EFA), a key benchmark and broad measure of international markets, over the same period.

The Slowing Growth Factor

Still, there appears to be one major fundamental that’s dragging on biotech.

And that is the near consensus over a slowdown in growth for the group.

As Alan Clifton, chairman of the International Biotechnology Trust, pointed out:

“The biotechnology sector has enjoyed a period of exceptional performance over the past three years. In my view, value creation in the biotechnology sector will continue for the foreseeable future, though it may be wise to anticipate a more moderate pace of advance in the near term.”

If there’s anything an already-tired bull market doesn’t want to hear, it is the term “more moderate pace,” even if it is inevitable.

Still another negative sign is the number of initial public offerings (IPOs) in the sector — always a warning of a bubble forming in biotech land.

According to data firm Dealogic, there have been 22 initial public offerings in the pharma and biotech sector since the start of 2015. Those IPOs raised a total of $1.7 billion.

Exclusive  The Most Divisive Election in American History

This reflects high investor appetite for investing even in money-losing companies. The willingness to take on such risks in speculative biotech IPOs is eerily reminiscent of the dotcom bubble.

That resemblance is not lost on investors looking to book the gains before everyone heads for the door at the same time.

That’s why so many investors took profits over the past few weeks.

My Biotech Takeaway

While there has been a big run higher in the biotech sector over the past three years, I do not think we are in bubble territory just quite yet.

In fact, I see the recent pullback in biotech stocks as merely tracking trends in the broader market.

Pullbacks from time to time in a high-flying sector such as biotech are simply a consequence of what happens when traders get more nervous about locking in big gains.

This is hardly unprecedented.

Many traders called the end of the biotech boom last spring when the sector pulled back 25%. But those who exited biotechs then have regretted it ever since.

And though I fully expect this biotech boom to end with a bust, I believe any pullback in the biotech sector today is likely to be an attractive buying opportunity in the context of a long-term bull market.

And this has as much to do with market sentiment as with objective valuation.

As Sir John Templeton put it:

“Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria.”

And with all the handwringing about the imminent collapse of biotech, I see little euphoria in the biotech sector today.

Exclusive  Reviewing the Financial Ups and Downs of 2016

In case you missed it, I encourage you to read the e-letter column from last week about viewing world currencies through the Big Mac Index. I also invite you to comment in the space provided below.

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

One of the most significant stories for the stock market in 2015 has been the wholesale collapse of oil prices and the energy sector.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike Turner’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE